Meghamsh Kanuparthy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meghamsh Kanuparthy has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Frank W. Sellke
Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA
12 shared publications - Christopher Stone
Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA
11 shared publications - Kelsey C. Muir
Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA
7 shared publications - Md Ruhul Abid
Division of Cardiothoracic Surgery, Cardiovascular Research Center, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
7 shared publications - Mark Broadwin
The Warren Alpert Medical School of Brown University
6 shared publications Christopher Stone
5 shared publications
Latest Publications
- Open Access
- 13 February 2026
- Published by Elsevier in JTCVS Open
- Vol. 30
Gender disparities in Medicare billings among cardiothoracic surgeons
- 13 February 2026
- Published by Elsevier in JTCVS Open
- Vol. 30
Open AccessGender disparities in Medicare billings among cardiothoracic surgeons
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (2) , e323916
Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling
BACKGROUND: Ischemic heart disease is the leading cause of mortality and human suffering globally. It often leaves patients with residual symptomatic burden despite current optimized procedural and medical options. Sotagliflozin, a dual SGLT1/2 (sodium-glucose cotransporter 1 and 2) inhibitor, has emerged for its clinically evident ischemic cardiovascular benefits. We hypothesize that sotagliflozin treatment exerts direct myocardial benefits in ischemic heart disease, independent of comorbid conditions. METHODS: Yorkshire swine (n=22) underwent placement of an ameroid constrictor around the left circumflex coronary artery. Following a 2-week period in which the ameroid gradually closes, swine (n=18) were randomized to receive either 400 mg daily sotagliflozin (n=8) or no drug (n=10) for 5 weeks. Afterwards, swine underwent terminal harvest to acquire cardiac functional data with pressure-volume loops, myocardial perfusion by microsphere injection, and ventricular sectioning. To investigate the cellular and tissue-level impact of therapy, histology, immunoblotting, and high-throughput techniques were performed. RESULTS: Sotagliflozin swine had improved ejection fraction, cardiac output, and stroke work compared with no drug ( P P =0.04). Absolute blood flow to the ischemic myocardium was increased in the sotagliflozin group ( P =0.03). Sotagliflozin swine had a reduction in 3-nitrotyrosine and trichrome staining, representing decreased reactive nitrogen species and myocardial fibrosis ( P =0.03 for both). Molecularly, sotagliflozin swine demonstrated increased expression of endothelial nitric oxide synthase and superoxide dismutase 3 ( P =0.02, P =0.04; respectively), with upregulated arginine metabolism, protein kinase A/cyclic adenosine monophosphate signaling, as well as glycolysis, fatty acid oxidation, and citric acid cycle. CONCLUSIONS: Sotagliflozin treatment improved left ventricular function, myocardial perfusion, and diastolic relaxation, likely through reduced nitrosative stress and myocardial fibrosis, improved nitric oxide coupling, enhanced insulin signaling, and favorable metabolic shifts. This study suggests a potential role for sotagliflozin as a cardioprotective therapy in patients with ischemic heart disease beyond current treatment strategies.
- 1 February 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (2) , e323916
Open AccessSotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling
BACKGROUND: Ischemic heart disease is the leading cause of mortality and human suffering globally. It often leaves patients with residual symptomatic burden despite current optimized procedural and medical options. Sotagliflozin, a dual SGLT1/2 (sodium-glucose cotransporter 1 and 2) inhibitor, has emerged for its clinically evident ischemic cardiovascular benefits. We hypothesize that sotagliflozin treatment exerts direct myocardial benefits in ischemic heart disease, independent of comorbid conditions. METHODS: Yorkshire swine (n=22) underwent placement of an ameroid constrictor around the left circumflex coronary artery. Following a 2-week period in which the ameroid gradually closes, swine (n=18) were randomized to receive either 400 mg daily sotagliflozin (n=8) or no drug (n=10) for 5 weeks. Afterwards, swine underwent terminal harvest to acquire cardiac functional data with pressure-volume loops, myocardial perfusion by microsphere injection, and ventricular sectioning. To investigate the cellular and tissue-level impact of therapy, histology, immunoblotting, and high-throughput techniques were performed. RESULTS: Sotagliflozin swine had improved ejection fraction, cardiac output, and stroke work compared with no drug ( P P =0.04). Absolute blood flow to the ischemic myocardium was increased in the sotagliflozin group ( P =0.03). Sotagliflozin swine had a reduction in 3-nitrotyrosine and trichrome staining, representing decreased reactive nitrogen species and myocardial fibrosis ( P =0.03 for both). Molecularly, sotagliflozin swine demonstrated increased expression of endothelial nitric oxide synthase and superoxide dismutase 3 ( P =0.02, P =0.04; respectively), with upregulated arginine metabolism, protein kinase A/cyclic adenosine monophosphate signaling, as well as glycolysis, fatty acid oxidation, and citric acid cycle. CONCLUSIONS: Sotagliflozin treatment improved left ventricular function, myocardial perfusion, and diastolic relaxation, likely through reduced nitrosative stress and myocardial fibrosis, improved nitric oxide coupling, enhanced insulin signaling, and favorable metabolic shifts. This study suggests a potential role for sotagliflozin as a cardioprotective therapy in patients with ischemic heart disease beyond current treatment strategies.
- Open Access
Cellular and Molecular Mechanisms of SARS-CoV-2 Spike Protein-Induced Endothelial Dysfunction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by the viral spike proteins, which are key structural components that mediate host cell binding and entry and alter downstream signaling through multiple interactions with endothelial surface receptors. Endothelial dysfunction is a central consequence of COVID-19, contributing to vascular inflammation, barrier disruption, thrombosis, and multi-organ injury affecting the pulmonary, cardiovascular, cerebral, and renal systems. Emerging evidence demonstrates that spike protein-mediated effects, independent of productive viral infection, disrupt endothelial homeostasis through angiotensin-converting enzyme 2 (ACE2) dysregulation, integrin engagement, altered calcium signaling, junctional protein remodeling, oxidative stress, and pro-inflammatory and pro-apoptotic pathways. This review is intentionally focused on spike (S) protein-driven mechanisms of endothelial dysfunction; pathogenic vascular effects attributed to other SARS-CoV-2 structural proteins, including the nucleocapsid (N) protein, are beyond the scope of this discussion. In this review, we synthesize current experimental and translational data detailing the molecular mechanisms by which the SARS-CoV-2 spike protein drives endothelial dysfunction across multiple organ systems and discuss potential therapeutic strategies aimed at preserving endothelial integrity in acute COVID-19 and its long-term vascular sequela.
Open AccessCellular and Molecular Mechanisms of SARS-CoV-2 Spike Protein-Induced Endothelial Dysfunction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by the viral spike proteins, which are key structural components that mediate host cell binding and entry and alter downstream signaling through multiple interactions with endothelial surface receptors. Endothelial dysfunction is a central consequence of COVID-19, contributing to vascular inflammation, barrier disruption, thrombosis, and multi-organ injury affecting the pulmonary, cardiovascular, cerebral, and renal systems. Emerging evidence demonstrates that spike protein-mediated effects, independent of productive viral infection, disrupt endothelial homeostasis through angiotensin-converting enzyme 2 (ACE2) dysregulation, integrin engagement, altered calcium signaling, junctional protein remodeling, oxidative stress, and pro-inflammatory and pro-apoptotic pathways. This review is intentionally focused on spike (S) protein-driven mechanisms of endothelial dysfunction; pathogenic vascular effects attributed to other SARS-CoV-2 structural proteins, including the nucleocapsid (N) protein, are beyond the scope of this discussion. In this review, we synthesize current experimental and translational data detailing the molecular mechanisms by which the SARS-CoV-2 spike protein drives endothelial dysfunction across multiple organ systems and discuss potential therapeutic strategies aimed at preserving endothelial integrity in acute COVID-19 and its long-term vascular sequela.
- Open Access
- 1 December 2025
- Published by Elsevier in JTCVS Open
- Vol. 29, 101541
Uncontrolled hypertension contributes to vascular permeability after cardioplegic arrest and cardiopulmonary bypass
- 1 December 2025
- Published by Elsevier in JTCVS Open
- Vol. 29, 101541
Open AccessUncontrolled hypertension contributes to vascular permeability after cardioplegic arrest and cardiopulmonary bypass
- 10 October 2025
- Published by MyJove Corporation
- No. 224,p. e68490
JoVE Video Dataset
Despite breakthroughs in medical and procedural therapies for the treatment of cardiovascular disease, the need for translational large animal models has persisted to investigate diagnostic tools and treatment strategies. Swine represent an impeccably accurate and appropriate model for human cardiovascular disease, as their cardiac anatomy and physiology closely resemble that of humans, as well as their metabolic and proteomic profile. The induction of chronic myocardial ischemia to an area of the myocardium by using an ameroid constrictor accurately and easily emulates the common pathophysiologic process of atherosclerosis development in humans and subsequent myocardial response. Ameroid constrictors have been widely studied over the last 50 years providing rigorous evidence for its use; furthermore, we have over two decades of experience in efficiently and uniformly conducting this procedure. An important step within this protocol is performing coronary blood flow mapping to determine the area of greatest ischemia and areas with no ischemia by injecting isotope-labeled microspheres. The ability to perform coronary blood flow mapping precludes the necessary and labor-intensive use of cardiac MRI or PET imaging for perfusion studies and determination of the ischemic territory. The goal of this publication is to detail the correct placement of an ameroid constrictor on the proximal LCx and subsequent coronary perfusion mapping.
- 10 October 2025
- Published by MyJove Corporation
- No. 224,p. e68490
JoVE Video Dataset
Despite breakthroughs in medical and procedural therapies for the treatment of cardiovascular disease, the need for translational large animal models has persisted to investigate diagnostic tools and treatment strategies. Swine represent an impeccably accurate and appropriate model for human cardiovascular disease, as their cardiac anatomy and physiology closely resemble that of humans, as well as their metabolic and proteomic profile. The induction of chronic myocardial ischemia to an area of the myocardium by using an ameroid constrictor accurately and easily emulates the common pathophysiologic process of atherosclerosis development in humans and subsequent myocardial response. Ameroid constrictors have been widely studied over the last 50 years providing rigorous evidence for its use; furthermore, we have over two decades of experience in efficiently and uniformly conducting this procedure. An important step within this protocol is performing coronary blood flow mapping to determine the area of greatest ischemia and areas with no ischemia by injecting isotope-labeled microspheres. The ability to perform coronary blood flow mapping precludes the necessary and labor-intensive use of cardiac MRI or PET imaging for perfusion studies and determination of the ischemic territory. The goal of this publication is to detail the correct placement of an ameroid constrictor on the proximal LCx and subsequent coronary perfusion mapping.
- 10 October 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 224,p. e68490
A Clinically Relevant Swine Model of Chronic Myocardial Ischemia by Ameroid Constrictor Placement with Simultaneous Perfusion Mapping
Despite breakthroughs in medical and procedural therapies for the treatment of cardiovascular disease, the need for translational large animal models has persisted to investigate diagnostic tools and treatment strategies. Swine represent an impeccably accurate and appropriate model for human cardiovascular disease, as their cardiac anatomy and physiology closely resemble that of humans, as well as their metabolic and proteomic profile. The induction of chronic myocardial ischemia to an area of the myocardium by using an ameroid constrictor accurately and easily emulates the common pathophysiologic process of atherosclerosis development in humans and subsequent myocardial response. Ameroid constrictors have been widely studied over the last 50 years providing rigorous evidence for its use; furthermore, we have over two decades of experience in efficiently and uniformly conducting this procedure. An important step within this protocol is performing coronary blood flow mapping to determine the area of greatest ischemia and areas with no ischemia by injecting isotope-labeled microspheres. The ability to perform coronary blood flow mapping precludes the necessary and labor-intensive use of cardiac MRI or PET imaging for perfusion studies and determination of the ischemic territory. The goal of this publication is to detail the correct placement of an ameroid constrictor on the proximal LCx and subsequent coronary perfusion mapping.
- 10 October 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 224,p. e68490
A Clinically Relevant Swine Model of Chronic Myocardial Ischemia by Ameroid Constrictor Placement with Simultaneous Perfusion Mapping
Despite breakthroughs in medical and procedural therapies for the treatment of cardiovascular disease, the need for translational large animal models has persisted to investigate diagnostic tools and treatment strategies. Swine represent an impeccably accurate and appropriate model for human cardiovascular disease, as their cardiac anatomy and physiology closely resemble that of humans, as well as their metabolic and proteomic profile. The induction of chronic myocardial ischemia to an area of the myocardium by using an ameroid constrictor accurately and easily emulates the common pathophysiologic process of atherosclerosis development in humans and subsequent myocardial response. Ameroid constrictors have been widely studied over the last 50 years providing rigorous evidence for its use; furthermore, we have over two decades of experience in efficiently and uniformly conducting this procedure. An important step within this protocol is performing coronary blood flow mapping to determine the area of greatest ischemia and areas with no ischemia by injecting isotope-labeled microspheres. The ability to perform coronary blood flow mapping precludes the necessary and labor-intensive use of cardiac MRI or PET imaging for perfusion studies and determination of the ischemic territory. The goal of this publication is to detail the correct placement of an ameroid constrictor on the proximal LCx and subsequent coronary perfusion mapping.
- 22 August 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 222,p. e68545
Terminal Harvest Procedure of a Large Animal Model of Chronic Myocardial Ischemia with Hemodynamic Characterization and Perfusion Analysis
Reproducibility and research integrity are foundational tenets to scientific discovery, which are produced utilizing well-established, proven principles and protocols. Furthermore, with the ever-increasing prevalence and burden cardiovascular disease (CVD) places on individuals and society at large, it deems essential to cultivate robust and validated model for investigation. Our group utilizes a two-surgery protocol in a swine model that has been progressively refined over the last twenty years, in which we first induce chronic myocardial ischemia by placement of an ameroid constrictor mimicking the pathophysiology of coronary artery disease (CAD) in humans. The second and terminal procedure is a comprehensive and thoughtful collection of cardiac hemodynamic parameters as well as regional coronary perfusion, followed by beating heart euthanasia and detailed sectioning of the heart. Our lab uses isotope-labeled microspheres to analyze myocardial blood flow to the ischemic area as a powerful method to quantify collateralization due to experimental therapeutic agents. Furthermore, and likely the most important measurable cardiovascular outcome, we utilize left ventricular pressure-volume (PV) loop catheterization to measure a broad range of hemodynamic parameters. We hope by detailing the comprehensive cardiac analysis of our swine model of chronic myocardial ischemia, other researchers may improve and cultivate their own protocols and therapy investigation for the elimination of cardiovascular disease.
- 22 August 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 222,p. e68545
Terminal Harvest Procedure of a Large Animal Model of Chronic Myocardial Ischemia with Hemodynamic Characterization and Perfusion Analysis
Reproducibility and research integrity are foundational tenets to scientific discovery, which are produced utilizing well-established, proven principles and protocols. Furthermore, with the ever-increasing prevalence and burden cardiovascular disease (CVD) places on individuals and society at large, it deems essential to cultivate robust and validated model for investigation. Our group utilizes a two-surgery protocol in a swine model that has been progressively refined over the last twenty years, in which we first induce chronic myocardial ischemia by placement of an ameroid constrictor mimicking the pathophysiology of coronary artery disease (CAD) in humans. The second and terminal procedure is a comprehensive and thoughtful collection of cardiac hemodynamic parameters as well as regional coronary perfusion, followed by beating heart euthanasia and detailed sectioning of the heart. Our lab uses isotope-labeled microspheres to analyze myocardial blood flow to the ischemic area as a powerful method to quantify collateralization due to experimental therapeutic agents. Furthermore, and likely the most important measurable cardiovascular outcome, we utilize left ventricular pressure-volume (PV) loop catheterization to measure a broad range of hemodynamic parameters. We hope by detailing the comprehensive cardiac analysis of our swine model of chronic myocardial ischemia, other researchers may improve and cultivate their own protocols and therapy investigation for the elimination of cardiovascular disease.
- 22 August 2025
- Published by MyJove Corporation
- No. 222,p. e68545
JoVE Video Dataset
Reproducibility and research integrity are foundational tenets to scientific discovery, which are produced utilizing well-established, proven principles and protocols. Furthermore, with the ever-increasing prevalence and burden cardiovascular disease (CVD) places on individuals and society at large, it deems essential to cultivate robust and validated model for investigation. Our group utilizes a two-surgery protocol in a swine model that has been progressively refined over the last twenty years, in which we first induce chronic myocardial ischemia by placement of an ameroid constrictor mimicking the pathophysiology of coronary artery disease (CAD) in humans. The second and terminal procedure is a comprehensive and thoughtful collection of cardiac hemodynamic parameters as well as regional coronary perfusion, followed by beating heart euthanasia and detailed sectioning of the heart. Our lab uses isotope-labeled microspheres to analyze myocardial blood flow to the ischemic area as a powerful method to quantify collateralization due to experimental therapeutic agents. Furthermore, and likely the most important measurable cardiovascular outcome, we utilize left ventricular pressure-volume (PV) loop catheterization to measure a broad range of hemodynamic parameters. We hope by detailing the comprehensive cardiac analysis of our swine model of chronic myocardial ischemia, other researchers may improve and cultivate their own protocols and therapy investigation for the elimination of cardiovascular disease.
- 22 August 2025
- Published by MyJove Corporation
- No. 222,p. e68545
JoVE Video Dataset
Reproducibility and research integrity are foundational tenets to scientific discovery, which are produced utilizing well-established, proven principles and protocols. Furthermore, with the ever-increasing prevalence and burden cardiovascular disease (CVD) places on individuals and society at large, it deems essential to cultivate robust and validated model for investigation. Our group utilizes a two-surgery protocol in a swine model that has been progressively refined over the last twenty years, in which we first induce chronic myocardial ischemia by placement of an ameroid constrictor mimicking the pathophysiology of coronary artery disease (CAD) in humans. The second and terminal procedure is a comprehensive and thoughtful collection of cardiac hemodynamic parameters as well as regional coronary perfusion, followed by beating heart euthanasia and detailed sectioning of the heart. Our lab uses isotope-labeled microspheres to analyze myocardial blood flow to the ischemic area as a powerful method to quantify collateralization due to experimental therapeutic agents. Furthermore, and likely the most important measurable cardiovascular outcome, we utilize left ventricular pressure-volume (PV) loop catheterization to measure a broad range of hemodynamic parameters. We hope by detailing the comprehensive cardiac analysis of our swine model of chronic myocardial ischemia, other researchers may improve and cultivate their own protocols and therapy investigation for the elimination of cardiovascular disease.
- Open Access
- 17 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177975
Sodium-glucose Cotransporter-2 Canagliflozin's impact on cardiovascular disease in the setting of metabolic syndrome: A proteomic analysis
- 17 July 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1003, 177975
Open AccessSodium-glucose Cotransporter-2 Canagliflozin's impact on cardiovascular disease in the setting of metabolic syndrome: A proteomic analysis
- Open Access
Impaired contractile response of human peripheral arterioles to angiotensin II after cardiopulmonary bypass